Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Rachael Siegel.
Journal of Immunology | 2011
Rachael Siegel; Joyce Eskdale; Grant Gallagher
The type III (λ) IFNs (IFN-λ1, IFN-λ2, and IFN-λ3) and their receptor are the most recently discovered IFN family. They are induced by viruses and mediate antiviral activity, but type III IFNs have an important, specific functional niche at the immune/epithelial interface, as well as in the regulation of Th2 cytokines. Their expression appears diminished in bronchial epithelial cells of rhinovirus-infected asthmatic individuals. We investigated the regulation of IFN-λ1 expression in human airway epithelial cells using reporter genes analysis, chromatin immunoprecipitation, small interfering RNA knockdown, and DNase footprinting. In this article, we define the c-REL/p65 NF-κB heterodimer and IRF-1 as key transcriptional activators and ZEB1, B lymphocyte-induced maturation protein 1, and the p50 NF-κB homodimer as key repressors of the IFN-λ1 gene. We further show that ZEB1 selectively regulates type III IFNs. To our knowledge, this study presents the first characterization of any type III IFN promoter in its native context and conformation in epithelial cells and can now be applied to understanding pathogenic dysregulation of IFN-λ1 in human disease.
Journal of Interferon and Cytokine Research | 2010
Grant Gallagher; Nicholas Megjugorac; Raymond Yu; Joyce Eskdale; Rachael Siegel; Elizabeth Tollar
The type-III interferons (IFNs) are the most recently discovered IFNs in the human immune system and have important, but as yet poorly characterized, functions in innate and adaptive immunity that complement their antiviral functions. It is now becoming clear that these type-III IFNs have a functional niche where epithelial surfaces interact with the adaptive immune system, that their antiviral capability is not as highly developed as that of the type-I IFNs, and that they have their own profile of immunomodulatory functions; specifically, they are key modulators of the T-helper (Th)2 response.
Cytokine | 2014
Adam Swider; Rachael Siegel; Joyce Eskdale; Grant Gallagher
Archive | 2015
Grant Gallagher; Joyce Eskdale; Rachael Siegel
Archive | 2014
Grant Gallagher; Joyce Eskdale; Rachael Siegel
Archive | 2014
Grant Gallagher; Joyce Eskdale; Rachael Siegel
Archive | 2014
Grant Gallagher; Joyce Eskdale; Rachael Siegel
Archive | 2013
Grant Gallagher; Rachael Siegel; Joyce Eskdale
Inflammatory Bowel Diseases | 2012
Grant Gallagher; Anne Marie Kinder; Rachael Siegel; Jane Friehling; Nicholas Megjugorac
Archive | 2010
Grant Gallagher; Rachael Siegel; Joyce Eskdale